Eli Lilly and (LLY) Quick Ratio: History & Chart

Eli Lilly and Company (LLY)LLYEli Lilly and Company

About Eli Lilly and Company

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Indianapolis, IN

50,000 employees

www.lilly.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: David A. Ricks

View full financials

LLY Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

1.10

QUICK RATIO (ACID-TEST) AVG TTM

1.12

QUICK RATIO (ACID-TEST) AVG 3Y

0.98

QUICK RATIO (ACID-TEST) AVG 5Y

0.97

QUICK RATIO (ACID-TEST) AVG 10Y

0.98

QUICK RATIO (ACID-TEST) AVG 15Y

1.10

QUICK RATIO (ACID-TEST) AVG 20Y

1.22

CURRENT VS TTM AVG

-1.59%

CURRENT VS 3Y AVG

+11.81%

CURRENT VS 5Y AVG

+13.93%

CURRENT VS 10Y AVG

+12.63%

CURRENT VS 15Y AVG

+0.08%

CURRENT VS 20Y AVG

-9.86%

SECTOR MEDIAN · HEALTHCARE

1.21

median of 79 covered companies

CURRENT VS SECTOR MEDIAN

-9.07%

vs the sector median at left

NAME	MARKET CAP	QUICK RATIO (ACID-TEST)	TTM	3Y	5Y
Eli Lilly and Company (LLY)	$1.08T	1.10	1.12	0.98	0.97
Johnson & Johnson (JNJ)vs ›	$617.78B	0.77	0.81	0.84	0.91
AbbVie Inc. (ABBV)vs ›	$443.24B	0.56	0.56	0.68	0.69
UnitedHealth Group Incorporated (UNH)vs ›	$376.34B	0.79	0.81	0.80	0.79
Merck & Co., Inc. (MRK)vs ›	$321.62B	1.30	1.23	1.17	1.09
Thermo Fisher Scientific Inc. (TMO)vs ›	$213.42B	1.53	1.41	1.34	1.37
Novo Nordisk A/S (NVO)vs ›	$209.19B	0.57	0.56	0.61	0.63
Amgen Inc. (AMGN)vs ›	$207.87B	0.90	0.93	1.02	1.14
Abbott Laboratories (ABT)vs ›	$184.11B	1.18	1.21	1.20	1.26
Gilead Sciences, Inc. (GILD)vs ›	$161.66B	1.31	1.38	1.29	1.26

NAME

MARKET CAP

QUICK RATIO (ACID-TEST)

TTM

Eli Lilly and Company (LLY)

$1.08T

1.10

1.12

0.98

0.97

Johnson & Johnson (JNJ)vs ›

$617.78B

0.77

0.81

0.84

0.91

AbbVie Inc. (ABBV)vs ›

$443.24B

0.56

0.68

0.69

UnitedHealth Group Incorporated (UNH)vs ›

$376.34B

0.79

0.81

0.80

0.79

Merck & Co., Inc. (MRK)vs ›

$321.62B

1.30

1.23

1.17

1.09

Thermo Fisher Scientific Inc. (TMO)vs ›

$213.42B

1.53

1.41

1.34

1.37

Novo Nordisk A/S (NVO)vs ›

$209.19B

0.57

0.56

0.61

0.63

Amgen Inc. (AMGN)vs ›

$207.87B

0.90

0.93

1.02

1.14

Abbott Laboratories (ABT)vs ›

$184.11B

1.18

1.21

1.20

1.26

Gilead Sciences, Inc. (GILD)vs ›

$161.66B

1.31

1.38

1.29

1.26

Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for Eli Lilly and Company (LLY)?

The quick ratio (acid-test) for LLY stock is 1.10.

Is Eli Lilly and Company's quick ratio (acid-test) high or low?

The quick ratio (acid-test) of 1.10 is 14% above its 5-year average of 0.97, near the high end of its 5-year range (0.73–1.24).

What is the TTM average quick ratio (acid-test) for Eli Lilly and Company (LLY)?

The TTM average quick ratio (acid-test) for LLY stock is 1.12.

What is the 3Y average quick ratio (acid-test) for Eli Lilly and Company (LLY)?

The 3Y average quick ratio (acid-test) for LLY stock is 0.98.

What is the 5Y average quick ratio (acid-test) for Eli Lilly and Company (LLY)?

The 5Y average quick ratio (acid-test) for LLY stock is 0.97.

What is the 10Y average quick ratio (acid-test) for Eli Lilly and Company (LLY)?

The 10Y average quick ratio (acid-test) for LLY stock is 0.98.

What is the 15Y average quick ratio (acid-test) for Eli Lilly and Company (LLY)?

The 15Y average quick ratio (acid-test) for LLY stock is 1.10.

What is the 20Y average quick ratio (acid-test) for Eli Lilly and Company (LLY)?

The 20Y average quick ratio (acid-test) for LLY stock is 1.22.

DATE	QUICK RATIO (ACID-TEST)
2026-03-31	1.10
2025-12-31	1.19
2025-09-30	1.24
2025-06-30	1.00
2025-03-31	1.06
2024-12-31	0.89
2024-09-30	0.97
2024-06-30	0.87
2024-03-31	1.03
2023-12-31	0.73
2023-09-30	0.82
2023-06-30	0.87
2023-03-31	1.02
2022-12-31	0.80
2022-09-30	0.88
2022-06-30	0.85
2022-03-31	0.98
2021-12-31	0.97
2021-09-30	1.02
2021-06-30	0.89
2021-03-31	1.10
2020-12-31	1.08
2020-09-30	1.06
2020-06-30	0.94
2020-03-31	0.86
2019-12-31	0.89
2019-09-30	0.88
2019-06-30	0.87
2019-03-31	0.85
2018-12-31	1.47
2018-09-30	1.53
2018-06-30	1.09
2018-03-31	1.01
2017-12-31	1.01
2017-09-30	1.03
2017-06-30	1.01
2017-03-31	0.86
2016-12-31	1.05
2016-09-30	1.15
2016-06-30	1.10
2016-03-31	1.09
2015-12-31	1.11
2015-09-30	1.10
2015-06-30	1.10
2015-03-31	1.05
2014-12-31	0.84
2014-09-30	1.22
2014-06-30	1.34
2014-03-31	1.52
2013-12-31	1.14
2013-09-30	1.27
2013-06-30	1.18
2013-03-31	1.28
2012-12-31	1.24
2012-09-30	1.65
2012-06-30	1.51
2012-03-31	1.55
2011-12-31	1.34
2011-09-30	1.47
2011-06-30	1.40
2011-03-31	1.64
2010-12-31	1.74
2010-09-30	1.89
2010-06-30	1.63
2010-03-31	1.73
2009-12-31	1.47
2009-09-30	1.43
2009-06-30	1.14
2009-03-31	1.05
2008-12-31	0.76
2008-09-30	1.66
2008-06-30	1.93
2008-03-31	2.38
2007-12-31	1.86
2007-09-30	1.95
2007-06-30	1.59
2007-03-31	1.68
2006-12-31	1.46
2006-09-30	1.95
2006-06-30	1.83
2006-03-31	1.85
2005-12-31	1.56
2005-09-30	1.96
2005-06-30	1.39
2005-03-31	1.68
2004-12-31	1.39
2004-09-30	1.15
2004-06-30	1.00
2004-03-31	1.22
2003-12-31	1.22
2003-09-30	1.47
2003-06-30	1.22
2003-03-31	1.44
2002-12-31	1.25
2002-09-30	1.38
2002-06-30	1.33

DATE

QUICK RATIO (ACID-TEST)

2026-03-31

1.10

2025-12-31

1.19

2025-09-30

1.24

2025-06-30

1.00

2025-03-31

1.06

2024-12-31

0.89

2024-09-30

0.97

2024-06-30

0.87

2024-03-31

1.03

2023-12-31

0.73

2023-09-30

0.82

2023-06-30

0.87

2023-03-31

1.02

2022-12-31

0.80

2022-09-30

0.88

2022-06-30

0.85

2022-03-31

0.98

2021-12-31

0.97

2021-09-30

1.02

2021-06-30

0.89

2021-03-31

1.10

2020-12-31

1.08

2020-09-30

1.06

2020-06-30

0.94

2020-03-31

0.86

2019-12-31

0.89

2019-09-30

0.88

2019-06-30

0.87

2019-03-31

0.85

2018-12-31

1.47

2018-09-30

1.53

2018-06-30

1.09

2018-03-31

1.01

2017-12-31

1.01

2017-09-30

1.03

2017-06-30

1.01

2017-03-31

0.86

2016-12-31

1.05

2016-09-30

1.15

2016-06-30

1.10

2016-03-31

1.09

2015-12-31

1.11

2015-09-30

1.10

2015-06-30

1.10

2015-03-31

1.05

2014-12-31

0.84

2014-09-30

1.22

2014-06-30

1.34

2014-03-31

1.52

2013-12-31

1.14

2013-09-30

1.27

2013-06-30

1.18

2013-03-31

1.28

2012-12-31

1.24

2012-09-30

1.65

2012-06-30

1.51

2012-03-31

1.55

2011-12-31

1.34

2011-09-30

1.47

2011-06-30

1.40

2011-03-31

1.64

2010-12-31

1.74

2010-09-30

1.89

2010-06-30

1.63

2010-03-31

1.73

2009-12-31

1.47

2009-09-30

1.43

2009-06-30

1.14

2009-03-31

1.05

2008-12-31

0.76

2008-09-30

1.66

2008-06-30

1.93

2008-03-31

2.38

2007-12-31

1.86

2007-09-30

1.95

2007-06-30

1.59

2007-03-31

1.68

2006-12-31

1.46

2006-09-30

1.95

2006-06-30

1.83

2006-03-31

1.85

2005-12-31

1.56

2005-09-30

1.96

2005-06-30

1.39

2005-03-31

1.68

2004-12-31

1.39

2004-09-30

1.15

2004-06-30

1.00

2004-03-31

1.22

2003-12-31

1.22

2003-09-30

1.47

2003-06-30

1.22

2003-03-31

1.44

2002-12-31

1.25

2002-09-30

1.38

2002-06-30

1.33

Quick Ratio (Acid-Test): 1.10

LLY Quick Ratio

LLY Average Quick Ratio (Acid-Test) Chart

LLY Current vs Average Quick Ratio (Acid-Test) Chart

LLY Quick Ratio (Acid-Test) Metrics

LLY Competitors' Quick Ratio (Acid-Test)

Liquidity Comparison

Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio (Acid-Test) FAQ

LLY Quick Ratio (Acid-Test) History

Related Metrics